Business
Press Release Apr 30 2025
Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg".
About this update from Strides Pharma Science Ltd
Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg". View Attachment
View stock analysis, news, and events for Strides Pharma Science Ltd